Healthcare Feb 03, 2021 09:42 AM (GMT+8) · EqualOcean
On February 3, AI drug R & D enterprise Jingtai technology and high throughput single cell sequencing technology company xingeyuan biotechnology announced the signing of a strategic cooperation agreement. The two sides will combine the advantages of their respective platforms in target screening and new drug discovery, and jointly carry out new drug research and development for several potential targets of common tumors in Asian population, so as to provide a new generation of innovative drugs for cancer molecular targeted therapy. It is reported that in the specific cooperation, new Geyuan will use its single-cell sequencing data platform and target screening platform to evaluate and recommend potential targets for common tumors in Asia. Jingtai artificial intelligence research and development center of Jingtai technology will complete the discovery and design of new drugs, and recommend preclinical candidate compounds. The two sides will jointly verify and optimize the drug activity and effectiveness .

This text is a result of machine translation.